Use of Varenicline vs. Bupropion and Risk of Psychiatric Adverse Events

被引：0
|
作者：
Pasternak, Bjorn [1 ]
Svanstrom, Henrik [1 ]
Hviid, Anders [1 ]
机构：
[1] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2013年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
774
引用
收藏
页码：389 / 389
页数：1
相关论文
共 50 条
  • [1] Use of varenicline versus bupropion and risk of psychiatric adverse events
    Pasternak, Bjorn
    Svanstrom, Henrik
    Hviid, Anders
    ADDICTION, 2013, 108 (07) : 1336 - 1343
  • [2] Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation
    Mahmoudi, M.
    Coleman, C. I.
    Sobieraj, D. M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (02) : 171 - 182
  • [3] Varenicline vs Bupropion and Placebo for Smoking Cessation
    Bowman, Thomas S.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2007, 1 (05) : 357 - 357
  • [4] No increased risk of depression with varenicline, bupropion
    Reactions Weekly, 2013, 1480 (1) : 4 - 4
  • [5] Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment
    Cinciripini, Paul M.
    Green, Charles E.
    Robinson, Jason D.
    Karam-Hage, Maher
    Engelmann, Jeffrey M.
    Minnix, Jennifer A.
    Wetter, David W.
    Versace, Francesco
    PSYCHOPHARMACOLOGY, 2017, 234 (11) : 1769 - 1779
  • [6] Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment
    Paul M. Cinciripini
    Charles E. Green
    Jason D. Robinson
    Maher Karam-Hage
    Jeffrey M. Engelmann
    Jennifer A. Minnix
    David W. Wetter
    Francesco Versace
    Psychopharmacology, 2017, 234 : 1769 - 1779
  • [7] Orthokeratology vs. Spectacles: Adverse Events and Discontinuations
    Santodomingo-Rubido, Jacinto
    Villa-Collar, Cesar
    Gilmartin, Bernard
    Gutierrez-Ortega, Ramon
    OPTOMETRY AND VISION SCIENCE, 2012, 89 (08) : 1133 - 1139
  • [8] Serious adverse CV events with varenicline
    Reactions Weekly, 2011, 1360 (1) : 5 - 5
  • [9] Varenicline not linked with neuropsychiatric adverse events
    Reactions Weekly, 2013, 1476 (1) : 2 - 2
  • [10] Infliximab: elevated risk of psychiatric adverse events
    Reactions Weekly, 2020, 1805 (1) : 9 - 9
12345